Despite available antivirals and vaccines, influenza continues to be a major cause of
mortality worldwide. Vaccination generally induces an effective, but strain-specific antibody …

Vaccines are the gold standard for the control and prevention of infectious diseases, but a
number of important human diseases remain challenging targets for vaccine development …

The diversified classification and continuous alteration of influenza viruses underscore for
antivirals and vaccines that can counter a broad range of influenza subtypes. Hemagglutinin …

The antigenic diversity of human influenza viruses represents a challenge to the
development of vaccines with durable immune protection. In addition, small molecule anti …

Human monoclonal antibodies have been identified which neutralize broad spectra of
influenza A or B viruses. Here, we dissect the mechanisms by which such antibodies …

Current influenza virus vaccines rely upon the accurate prediction of circulating virus strains
months in advance of the actual influenza season in order to allow time for vaccine …

Highlights•Novel single cell technologies have enabled rapid generation of human
monoclonal antibodies.•These technologies have identified broadly neutralizing mAbs that …

Influenza virus is a respiratory pathogen that can cause disease in humans, with symptoms
ranging from mild to life-threatening. The vast majority of influenza virus infections in …

Influenza hemagglutinin (HA) is the major surface glycoprotein on influenza viruses and
mediates viral attachment and subsequent fusion with host cells. The HA is the major target …

Introduction: Antibodies directed against influenza virus execute their protective function by
exploiting a variety of effector mechanisms. Neutralizing antibodies have been thoroughly …